Page last updated: 2024-12-06

deoxoartemisinin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

deoxoartemisinin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14433155
CHEMBL ID2367467
SCHEMBL ID14516429
MeSH IDM0175983

Synonyms (5)

Synonym
deoxoartemisinin
CHEMBL2367467
BOQMASYCUFVXCR-LHJKONGQSA-N
SCHEMBL14516429
(1s,4s,5r,8s,9r,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID151852Antimalarial activity against Plasmodium berghei infected mice (Mus musculus) at 160 mg/kg dose; active in 2 of 51990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID151970Antimalarial activity against Plasmodium berghei infected mice (Mus musculus) at 20 mg/kg dose; n=51990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID151975Antimalarial activity against Plasmodium berghei infected mice (Mus musculus) at 80 mg/kg dose;n=51990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID151973Antimalarial activity against Plasmodium berghei infected mice (Mus musculus) at 40 mg/kg dose; n=51990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID151974Antimalarial activity against Plasmodium berghei infected mice (Mus musculus) at 640 mg/kg dose; n=51990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID24219Calculated partition coefficient (clogP) (Tsar)1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9.
AID158400In vitro antimalarial activity against drug-resistant Plasmodium falciparum D61995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and antimalarial activities of 12 beta-allyldeoxoartemisinin and its derivatives.
AID159182Relative in vitro activity compared to artemisinin against Plasmodium falciparum D6 (Sierra Leone)1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9.
AID28256Half life was reported2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID100410Antileishmanial activity of compound against leishmania donovani was determined in luciferase assay2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Structure-activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria.
AID159181Relative in vitro activity compared to artemisinin against Plasmodium falciparum Indochina W21996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9.
AID151972Antimalarial activity against Plasmodium berghei infected mice (Mus musculus) at 320 mg/kg dose; active in 2 of 51990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID262123Antiangiogenic activity at chorioallantoic membrane of chick embryo at 5 nmol per egg2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane.
AID1656212Antimalarial activity against Plasmodium falciparum W22019European journal of medicinal chemistry, Feb-01, Volume: 163Current scenario of artemisinin and its analogues for antimalarial activity.
AID158527In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 (Indochina)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID1656211Antimalarial activity against Plasmodium falciparum D62019European journal of medicinal chemistry, Feb-01, Volume: 163Current scenario of artemisinin and its analogues for antimalarial activity.
AID24218Calculated partition coefficient (clogP)1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9.
AID158526In vitro antimalarial activity against mefloquine-resistant Plasmodium falciparum D6 (Sierra Leone)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID158520In vitro antimalarial activity against drug-resistant Plasmodium falciparum W-21995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and antimalarial activities of 12 beta-allyldeoxoartemisinin and its derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (24.00)18.2507
2000's12 (48.00)29.6817
2010's7 (28.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (96.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]